Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the closing of its previously announced underwritten public offering of 28,452,381 shares of common stock, including 4,642,857 shares of common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at $4.20 per share. In addition, in lieu of shares of common stock, Savara sold to cer. ...